Tallini G - Search Results

1

Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O. Baloch ZW, et al. Among authors: tallini g. Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14. Endocr Pathol. 2022. PMID: 35288841 Review.

2

Oncocytic neoplasms of the thyroid gland.

Tallini G, Carcangiu ML, Rosai J. Tallini G, et al. Acta Pathol Jpn. 1992 May;42(5):305-15. doi: 10.1111/j.1440-1827.1992.tb02879.x. Acta Pathol Jpn. 1992. PMID: 1636432 Review.

3

Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease.

Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, Costa J, Robbins R, Burrow GN, Rosai J. Tallini G, et al. J Clin Oncol. 1998 Mar;16(3):1158-66. doi: 10.1200/JCO.1998.16.3.1158. J Clin Oncol. 1998. PMID: 9508203

4

Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories.

Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML. Tallini G, et al. Am J Surg Pathol. 1999 Jun;23(6):678-85. doi: 10.1097/00000478-199906000-00007. Am J Surg Pathol. 1999. PMID: 10366150

5

RET oncogene activation in papillary thyroid carcinoma.

Tallini G, Asa SL. Tallini G, et al. Adv Anat Pathol. 2001 Nov;8(6):345-54. doi: 10.1097/00125480-200111000-00005. Adv Anat Pathol. 2001. PMID: 11707626 Review.

6

RET activation and clinicopathologic features in poorly differentiated thyroid tumors.

Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A, Tallini G. Santoro M, et al. Among authors: tallini g. J Clin Endocrinol Metab. 2002 Jan;87(1):370-9. doi: 10.1210/jcem.87.1.8174. J Clin Endocrinol Metab. 2002. PMID: 11788678

7

Molecular pathobiology of thyroid neoplasms.

Tallini G. Tallini G. Endocr Pathol. 2002 Winter;13(4):271-88. doi: 10.1385/ep:13:4:271. Endocr Pathol. 2002. PMID: 12665646 Review.

8

Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.

Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B. Wreesmann VB, et al. Among authors: tallini g. Cancer Res. 2004 Jun 1;64(11):3780-9. doi: 10.1158/0008-5472.CAN-03-1460. Cancer Res. 2004. PMID: 15172984

9

Three-dimensional reconstruction of vessel distribution in benign and malignant lesions of thyroid.

Foschini MP, Papotti M, Parmeggiani A, Tallini G, Castaldini L, Meringolo D, Eusebi V. Foschini MP, et al. Among authors: tallini g. Virchows Arch. 2004 Aug;445(2):189-98. doi: 10.1007/s00428-004-1035-z. Epub 2004 Jun 8. Virchows Arch. 2004. PMID: 15185073

10

Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.

Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA. Liu J, et al. Among authors: tallini g. Cancer. 2006 Sep 15;107(6):1255-64. doi: 10.1002/cncr.22138. Cancer. 2006. PMID: 16900519 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

285 results

Search Page